Oramed Pharmaceuticals Inc. (ORMP) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Oramed Pharmaceuticals Inc. (ORMP) closed at USD 4.14 on 2026-10-14, a change of +88.2 % over the past year, with a market capitalization of USD 171.07M.

Oramed Pharmaceuticals Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Oramed Pharmaceuticals Inc. key figures

Previous close

USD 4.14 (2026-10-14)

1-year change

+88.2 %

Market cap

USD 171.07M

Enterprise value

USD 124M

P/E ratio (trailing)

1.01

P/E ratio (forward)

-52.25

EPS (trailing)

4.13

EPS (forward)

-0.08

PEG ratio

n/a

Price to book

0.54

Revenue growth

n/a

Earnings growth

493.5 %

Dividend per share (trailing)

0.00

Short ratio

7.52

Employees

n/a

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Oramed Pharmaceuticals Inc. and compare it with other stocks.